Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Nexvet Biopharma plc | d939161dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
June 8, 2015
Date of report (Date of earliest event reported)
Nexvet Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
| Ireland | 001-36828 | 98-1205017 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
National Institute for Bioprocessing Research and Training
Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
(Address of principal executive offices, including Zip Code)
+353 (1) 901 0339
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
The Brazilian regulatory authority (ANVISA) imposes certain requirements regarding segregation of human and veterinary manufacturing areas. In light of costs associated with these requirements, Nexvet Biopharma public limited company (the “Company”) and its prior manufacturer, Lonza Sales AG, were unable to agree on acceptable terms for commercial supply.
On June 8, 2015, the Company issued a press release regarding its new manufacturing arrangement with Fujifilm. The Company’s press release is filed herewith as Exhibit 99.1 and incorporated herein by reference. Fujifilm has advised the Company that it can satisfy the applicable segregation requirements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit |
Description | |
| 99.1 | Press release dated June 8, 2015 regarding manufacturing arrangements. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nexvet Biopharma public limited company | ||
| By: | /s/ Mark Heffernan, Ph.D | |
| Name: | Mark Heffernan | |
| Its: | Chief Executive Officer | |
Date: June 8, 2015